Microvesicles as biomarkers in NAFLD : a clinician’s point of view
Prof Rautou, France, sheds light on microvesicles, which reflect apoptosis and cell activation. He discusses what we know about microvesicles in NASH and the rationale to consider them as biomarkers in liver disease.
Read More
Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.
Several studies have investigated the association between serum uric acid and metabolic
syndrome / NAFLD. Read More
Experimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.
In a CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis, S. Lefere et al. studied the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis.
Read MoreMicrovesicles as NAFLD biomarkers: a clinician’s point of view by Prof. P. E. Rautou
Prof Rautou, France, sheds light on microvesicles, which reflect apoptosis and cell activation. He discusses what we know about microvesicles in NASH and the rationale to consider them as biomarkers in liver disease.
Read MoreNon-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.
Experimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.
Why are we linking PPAR agonists and lipids ?
Prof Sacks, Harvard Medical School, discusses the link between PPAR agonists and plasma lipid risk factors for cardiovascular disease. He explains how free fatty acids go to the liver and become lipotoxic. This activates inflammation in the liver which in turn reacts.
Read More
Metabolic liver disease in diabetes – from mechanisms to clinical trials.
Non-alcoholic fatty liver disease (NAFLD) is tightly associated with the most frequent metabolic disorders, such as obesity, metabolic syndrome, and type 2 diabetes mellitus (T2DM).
Read More
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.
. de Gottardi et al. (Gastroenterology and Hepatology, Ente Ospedaliero Cantonale, Lugano, Switzerland) present a case of SARS-CoV-2 infection reported in the literature in a liver transplanted patient
Read MoreThe link between lipids and PPARs in NASH by Prof. F. Sacks
Prof Sacks, Harvard Medical School, discusses the link between PPAR agonists and plasma lipid risk factors for cardiovascular disease. He explains how free fatty acids go to the liver and become lipotoxic. This activates inflammation in the liver which in turn reacts.
Read More